- Home
- SYRE vs CII Comparison
SYRE vs CII Comparison
Compare SYRE & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYRE | CII |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SYRE | CII |
|---|---|---|
| Price | $33.85 | $23.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $55.50 | N/A |
| AVG Volume (30 Days) | ★ 652.6K | 78.8K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.91 | $16.76 |
| 52 Week High | $34.54 | $19.81 |
Technical Indicators
Market Signals| Indicator | SYRE | CII |
|---|---|---|
| Relative Strength Index (RSI) | 78.25 | 41.90 |
| Support Level | $28.16 | $23.12 |
| Resistance Level | $34.54 | $26.17 |
| Average True Range (ATR) | 1.94 | 0.51 |
| MACD | 0.70 | -0.15 |
| Stochastic Oscillator | 92.54 | 4.92 |
Price Performance
Historical ComparisonAbout SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.